Comparative Pharmacology
Head-to-head clinical analysis: BROMANATE DM versus BROMANYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMANATE DM versus BROMANYL.
BROMANATE DM vs BROMANYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist; it also inhibits serotonin reuptake and acts on the cough center. Brompheniramine is a first-generation antihistamine that antagonizes histamine H1 receptors.
Bromanyl is a synthetic opioid analgesic that acts as a selective agonist at mu-opioid receptors, producing analgesia, sedation, and euphoria. It also exhibits weak antagonism at NMDA receptors, which may contribute to its analgesic effects and reduced tolerance development.
2.5 mg orally three times daily (every 8 hours); maximum 10 mg in 24 hours.
10 mg orally three times daily
None Documented
None Documented
Brompheniramine: 24.9 ± 9.3 hours. Dextromethorphan: 3-4 hours for extensive metabolizers (CYP2D6); 24-48 hours for poor metabolizers. Clinical context: Steady state reached in ~5 days for brompheniramine; accumulation in poor metabolizers may require dose adjustment.
Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged to 24-36 hours in severe hepatic impairment, requiring dose adjustment.
Brompheniramine is primarily excreted via renal elimination (approximately 70-85% as metabolites and unchanged drug). Dextromethorphan and its metabolites are excreted renally (about 60% as unchanged dextromethorphan and dextrorphan glucuronide conjugates). Biliary/fecal excretion accounts for the remainder.
Renal excretion of unchanged drug accounts for 30-40% of elimination; hepatic metabolism to inactive glucuronide conjugates accounts for 50-60%; fecal excretion is minimal (<5%).
Category C
Category C
Cough and Cold Combination
Cough and Cold Combination